AlzheimeramyloidAlzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder that is characterized by memory loss and a decline in activities of daily life. More than 50 million people
In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated disease progression and tau spreading, yet the mechanisms underlying faster disease manifestation are unknown. To address this, we combined resting-state fMRI and longitudinal tau-PET in two independent samples of contro...
Alzheimer’s Disease (AD) contributes to most cases of dementia. Its prominent neuropathological features are the extracellular neuritic plaques and intercellular neurofibrillary tangles composed of aggregated β-amyloid (Aβ) and hyperphosphorylated tau protein, respectively. In the past few decades, ...
Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer’s disease, but it remains unclear how these proteins interact to promote disease. Here, by combining cross-sectional and longitudinal molecular imaging and network connectivity analyses in living humans, we identified two amyloid...
for the Alzheimer’s Disease Neuroimaging Initiative Contributions J. K. Seong and C. H. Lyoo had full access to all the data in the study and took responsibility for the data's integrity and the data analysis's accuracy. S. W. Kim, H. Cho, J. K. Seong, and C. H. Lyoo planned...
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD). 开...
Barghorn S, Davies P, Mandelkow E (2004) Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta- structure in the core domain. Biochemistry 43:1694–1703. https://doi.org/10. 1021/bi0357006 4. Berger Z, Roder H, Hanna A, Carlson A, ...
Keywords: Tauopathies, Alzheimer's disease; tau structure; tau aggregation, Alzheimer's disease diagnosis, Amyloid Introduction The investigation of tau molecular structure covers its primary sequence, local elements of secondary structure and global fold and, finally, complex formation and aggre- gation...
Alzheimer's disease (AD) is the leading cause of dementia, accounting for more than 60% of total dementia cases worldwide [1]. Pathologically, AD is characterized by the deposition of amyloid-β (Aβ) peptides in the brain parenchyma and the accumulation of hyperphosphorylated tau proteins ...
Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer’s disease and related human tauopathies. There is a growing body of evidence indicating that pathological tau species can travel from cell to cell and spread the pathology t